A clinical study for people living with alcohol-related liver disease (ARLD)

June 3, 2026

The STARLIGHT Study is testing a study drug to see if it can reduce the harmful effects of alcohol on the liver in adults with ARLD who:
• Are 18 to 70 years of age.
• Have drunk alcohol within the last 4 months.
• Have been diagnosed with Alcohol-related Liver Disease

The study lasts for around 18 months and requires up to 22 visits to the hospital. You will be reimbursed for your time and travel.

For more information, visit https://en-gb.starlightgsk.com/ [PIN: 2291]
or https://clinicaltrials.gov/study/NCT06613698

Stopping drinking alcohol is recommended for people living with liver disease. However, this may not always be possible. You will still be able to participate in this study even if you have not stopped drinking.

Being in the study is voluntary, but by taking part you may help researchers better understand alcohol-related liver disease and help people with this condition in the future.

Participating hospitals in Bristol, Cambridge, Leeds, Liverpool, London, Middlesbrough, Glasgow, Plymouth

To see if you’re eligible and to be referred, enter your details at SubjectWell: Registration – TrialSearch

More news

A new chapter for liver health: together we are Liver UK

A new chapter for liver health: together we are Liver UK

Today, we take the next step in that journey as Liver UK: a stronger, clearer and more united voice for liver health.
Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

The British Liver Trust welcomes the news that hundreds more liver transplants could be carried out after a new procedure that supplies a donor liver with oxygen before removal was approved by NICE for use in the NHS.   In-situ ...
New hope for people living with MASH as two treatments receive MHRA approval

New hope for people living with MASH as two treatments receive MHRA approval

People living with metabolic dysfunction-associated steatohepatitis (MASH) have received encouraging news, with the UK medicines regulator approving two treatments for the condition within the past month. The Medicines and Healthcare ...
No results found.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.